BeiGene (BGNE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

BGNE Stock Forecast

BeiGene stock forecast is as follows: an average price target of $267.33 (represents a 51.50% upside from BGNE’s last price of $176.45) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

BGNE Price Target

The average price target for BeiGene (BGNE) is $267.33 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $307.00 to $207.00. This represents a potential 51.50% upside from BGNE's last price of $176.45.

BGNE Analyst Ratings

Buy

According to 11 Wall Street analysts, BeiGene's rating consensus is 'Buy'. The analyst rating breakdown for BGNE stock is 0 'Strong Buy' (0.00%), 8 'Buy' (72.73%), 3 'Hold' (27.27%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

BeiGene Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 29, 2024	Rebecca Liang	Bernstein	$207.00	$207.82	-0.40%	17.31%
Sep 18, 2024	Reni Benjamin	JMP Securities	$288.00	$197.51	45.82%	63.22%
Aug 23, 2024	Matthew Harrison	Morgan Stanley	$307.00	$193.57	58.60%	73.99%
May 09, 2024	Kelly Shi	Jefferies	$283.00	$164.44	72.10%	60.39%
Jun 30, 2023	Rebecca Liang	Bernstein	$196.00	$178.46	9.83%	11.08%
Oct 13, 2022	Michael Schmidt	Guggenheim	$205.00	$151.30	35.49%	16.18%

The latest BeiGene stock forecast, released on Nov 29, 2024 by Rebecca Liang from Bernstein, set a price target of $207.00, which represents a -0.40% decrease from the stock price at the time of the forecast ($207.82), and a 17.31% increase from BGNE last price ($176.45).

BeiGene Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	4
Avg Price Target	$207.00	$207.00	$271.25
Last Closing Price	$176.45	$176.45	$176.45
Upside/Downside	17.31%	17.31%	53.73%

In the current month, the average price target of BeiGene stock is $207.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 17.31% increase as opposed to BeiGene's last price of $176.45. This month's average price target is down 0.00% compared to last quarter, and down -23.69% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 29, 2024	Bernstein	Market Perform	Market Perform	Hold
Nov 13, 2024	Cowen & Co.	Buy	Buy	Hold
Sep 18, 2024	Johnson Rice		Market Perform	Initialise
Sep 18, 2024	JMP Securities	Market Outperform	Outperform	Initialise
Sep 18, 2024	JMP Securities		Market Outperform	Initialise
Aug 23, 2024	Morgan Stanley	Overweight	Overweight	Hold
Aug 08, 2024	Citigroup	Buy	Buy	Hold
Jul 22, 2024	Jefferies	Buy	Buy	Hold
May 09, 2024	Cowen & Co.	Buy	Buy	Hold
May 09, 2024	Jefferies	Buy	Buy	Hold
Apr 08, 2024	Bank of America Securities	Neutral	Neutral	Hold
Sep 21, 2023	Citigroup	Buy	Buy	Hold
Jul 17, 2023	Citigroup		Buy	Initialise
Jun 30, 2023	Bernstein		Market Perform	Downgrade
Dec 12, 2022	Canaccord Genuity	Buy	Buy	Hold
Oct 13, 2022	Guggenheim		Buy	Upgrade
Feb 28, 2022	SVB Leerink	Outperform	Outperform	Hold

BeiGene's last stock rating was published by Bernstein on Nov 29, 2024. The company gave BGNE a "Market Perform" rating, the same as its previous rate.

BeiGene Financial Forecast

BeiGene Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$781.31M	$595.26M	$447.80M	$380.10M	$387.63M	$341.57M	$306.63M	$213.98M	$206.44M	$149.99M	$605.87M	$100.10M	$91.08M	$65.64M	$52.06M	$56.89M	$50.14M
Avg Forecast	$1.37B	$1.29B	$1.27B	$1.24B	$1.21B	$1.16B	$1.12B	$1.07B	$1.05B	$983.26M	$810.34M	$670.09M	$637.01M	$596.75M	$501.07M	$444.20M	$388.17M	$385.69M	$313.18M	$260.37M	$214.58M	$186.26M	$175.82M	$258.05M	$121.53M	$86.28M	$64.76M	$49.12M	$60.25M	$65.43M
High Forecast	$1.42B	$1.34B	$1.32B	$1.29B	$1.25B	$1.21B	$1.16B	$1.11B	$1.07B	$1.01B	$810.34M	$670.09M	$694.19M	$601.85M	$520.15M	$461.11M	$402.95M	$385.69M	$313.18M	$260.37M	$214.58M	$186.26M	$175.82M	$258.05M	$121.53M	$86.28M	$64.76M	$49.12M	$60.25M	$65.43M
Low Forecast	$1.31B	$1.24B	$1.21B	$1.19B	$1.15B	$1.11B	$1.07B	$1.02B	$1.04B	$955.26M	$810.34M	$670.09M	$592.44M	$591.65M	$479.65M	$425.21M	$371.58M	$385.69M	$313.18M	$260.37M	$214.58M	$186.26M	$175.82M	$258.05M	$121.53M	$86.28M	$64.76M	$49.12M	$60.25M	$65.43M
# Analysts	1	1	1	1	1	1	1	2	6	3	3	3	6	4	4	4	2	4	4	4	3	3	3	3	4	6	4	4	7	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1.31%	1.19%	1.01%	0.98%	1.01%	1.09%	1.18%	1.00%	1.11%	0.85%	2.35%	0.82%	1.06%	1.01%	1.06%	0.94%	0.77%

BeiGene's average Quarter revenue forecast for Dec 23 based on 6 analysts is $637.01M, with a low forecast of $592.44M, and a high forecast of $694.19M. BGNE's average Quarter revenue forecast represents a -18.47% decrease compared to the company's last Quarter revenue of $781.31M (Sep 23).

BeiGene EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	6	3	3	3	6	4	4	4	2	4	4	4	3	3	3	3	4	6	4	4	7	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	$-133.97M	$-296.38M	$-371.26M	$-468.43M	$-422.16M	$-439.21M	$-443.10M	$-586.62M	$-420.90M	$-469.04M	$71.50M	$-474.24M	$-425.30M	$-328.81M	$-354.43M	$-373.02M	$-306.55M
Avg Forecast	$-1.22B	$-1.15B	$-1.13B	$-1.11B	$-1.08B	$-1.04B	$-996.73M	$-955.60M	$-933.50M	$-876.56M	$-722.40M	$-545.09M	$-567.88M	$-531.99M	$-446.69M	$-495.54M	$-391.61M	$-343.69M	$-279.07M	$-450.49M	$-191.22M	$-165.98M	$-156.67M	$144.78M	$-108.30M	$-76.88M	$-57.71M	$-365.39M	$-53.69M	$-58.31M
High Forecast	$-1.17B	$-1.10B	$-1.08B	$-1.06B	$-1.03B	$-992.27M	$-954.14M	$-911.36M	$-924.94M	$-851.60M	$-722.40M	$-436.07M	$-528.14M	$-527.44M	$-427.60M	$-396.43M	$-313.29M	$-343.69M	$-279.07M	$-360.39M	$-191.22M	$-165.98M	$-156.67M	$173.74M	$-108.30M	$-76.88M	$-57.71M	$-292.31M	$-53.69M	$-58.31M
Low Forecast	$-1.27B	$-1.20B	$-1.17B	$-1.15B	$-1.12B	$-1.08B	$-1.03B	$-990.99M	$-950.63M	$-901.52M	$-722.40M	$-654.11M	$-618.86M	$-536.54M	$-463.70M	$-594.65M	$-469.94M	$-343.69M	$-279.07M	$-540.59M	$-191.22M	$-165.98M	$-156.67M	$115.83M	$-108.30M	$-76.88M	$-57.71M	$-438.47M	$-53.69M	$-58.31M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.25%	0.66%	0.75%	1.20%	1.23%	1.57%	0.98%	3.07%	2.54%	2.99%	0.49%	4.38%	5.53%	5.70%	0.97%	6.95%	5.26%

3 analysts predict BGNE's average Quarter EBITDA for Jun 21 to be $-156.67M, with a high of $-156.67M and a low of $-156.67M. This is -319.13% lower than BeiGene's previous annual EBITDA (Mar 21) of $71.50M.

BeiGene Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	6	3	3	3	6	4	4	4	2	4	4	4	3	3	3	3	4	6	4	4	7	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$215.41M	$-381.14M	$-348.43M	$-445.33M	$-557.56M	$-571.45M	$-434.27M	$-585.65M	$-413.86M	$-480.34M	$66.50M	$-472.75M	$-425.22M	$-335.20M	$-363.74M	$-388.06M	$-307.36M
Avg Forecast	$110.78M	$55.02M	$40.80M	$14.53M	$-21.01M	$-31.12M	$-43.77M	$-87.04M	$-97.40M	$-117.97M	$-231.86M	$-599.93M	$-369.47M	$-358.46M	$-355.98M	$-545.39M	$-390.97M	$-409.29M	$-419.65M	$-495.81M	$-520.67M	$-492.12M	$-391.46M	$134.65M	$-442.85M	$-431.36M	$-500.01M	$-374.98M	$-502.59M	$-404.29M
High Forecast	$116.27M	$57.75M	$42.82M	$15.25M	$-19.84M	$-29.39M	$-41.34M	$-47.87M	$-6.86M	$-111.42M	$-218.98M	$-479.94M	$-115.85M	$-338.55M	$-336.20M	$-436.31M	$-312.78M	$-409.29M	$-419.65M	$-396.65M	$-520.67M	$-492.12M	$-391.46M	$161.58M	$-442.85M	$-431.36M	$-500.01M	$-299.99M	$-502.59M	$-404.29M
Low Forecast	$104.63M	$51.96M	$38.54M	$13.73M	$-22.05M	$-32.66M	$-45.93M	$-126.21M	$-178.33M	$-123.81M	$-243.33M	$-719.92M	$-508.80M	$-376.21M	$-373.60M	$-654.47M	$-469.16M	$-409.29M	$-419.65M	$-594.97M	$-520.67M	$-492.12M	$-391.46M	$107.72M	$-442.85M	$-431.36M	$-500.01M	$-449.98M	$-502.59M	$-404.29M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.60%	1.07%	0.64%	1.14%	1.36%	1.36%	0.88%	1.12%	0.84%	1.23%	0.49%	1.07%	0.99%	0.67%	0.97%	0.77%	0.76%

BeiGene's average Quarter net income forecast for Dec 23 is $-369.47M, with a range of $-508.80M to $-115.85M. BGNE's average Quarter net income forecast represents a -271.52% decrease compared to the company's last Quarter net income of $215.41M (Sep 23).

BeiGene SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	6	3	3	3	6	4	4	4	2	4	4	4	3	3	3	3	4	6	4	4	7	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$364.42M	$395.03M	$328.50M	$328.98M	$322.89M	$331.40M	$294.57M	$306.50M	$269.23M	$232.29M	$182.11M	$208.21M	$160.84M	$124.05M	$107.08M	$143.35M	$105.00M
Avg Forecast	$1.43B	$1.35B	$1.32B	$1.29B	$1.26B	$1.21B	$1.16B	$1.12B	$1.09B	$1.02B	$843.71M	$406.94M	$663.25M	$621.33M	$521.70M	$369.95M	$204.61M	$401.57M	$326.07M	$271.10M	$223.42M	$193.93M	$183.06M	$268.68M	$126.53M	$89.83M	$67.43M	$51.14M	$62.73M	$68.13M
High Forecast	$1.48B	$1.40B	$1.37B	$1.34B	$1.30B	$1.26B	$1.21B	$1.16B	$1.11B	$1.05B	$843.71M	$488.33M	$722.78M	$626.63M	$541.57M	$443.93M	$245.54M	$401.57M	$326.07M	$271.10M	$223.42M	$193.93M	$183.06M	$268.68M	$126.53M	$89.83M	$67.43M	$51.14M	$62.73M	$68.13M
Low Forecast	$1.37B	$1.29B	$1.26B	$1.24B	$1.20B	$1.16B	$1.11B	$1.06B	$1.08B	$994.60M	$843.71M	$325.55M	$616.83M	$616.02M	$499.41M	$295.96M	$163.69M	$401.57M	$326.07M	$271.10M	$223.42M	$193.93M	$183.06M	$268.68M	$126.53M	$89.83M	$67.43M	$51.14M	$62.73M	$68.13M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.59%	0.76%	0.89%	1.61%	0.80%	1.02%	1.09%	1.37%	1.39%	1.27%	0.68%	1.65%	1.79%	1.84%	2.09%	2.29%	1.54%

BeiGene's average Quarter SG&A projection for Dec 23 is $663.25M, based on 6 Wall Street analysts, with a range of $616.83M to $722.78M. The forecast indicates a 82.00% rise compared to BGNE last annual SG&A of $364.42M (Sep 23).

BeiGene EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	2	6	3	3	3	6	4	4	4	2	4	4	4	3	3	3	3	4	6	4	4	7	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.58	$-3.64	$-3.34	$-4.29	$-5.39	$-5.56	$-4.24	$-6.16	$-4.68	$-5.20	$0.78	$-5.20	$-4.81	$-4.29	$-4.70	$-6.37	$-5.07
Avg Forecast	$1.05	$0.52	$0.39	$0.14	$-0.20	$-0.29	$-0.41	$-0.82	$-0.92	$-1.11	$-2.19	$-3.09	$-3.49	$-3.38	$-3.36	$-3.66	$-4.64	$-3.91	$-4.01	$-4.12	$-4.97	$-4.70	$-3.74	$-1.90	$-4.23	$-4.12	$-4.78	$-4.85	$-4.80	$-3.86
High Forecast	$1.10	$0.55	$0.40	$0.14	$-0.19	$-0.28	$-0.39	$-0.45	$-0.06	$-1.05	$-2.07	$-2.92	$-1.09	$-3.20	$-3.17	$-3.46	$-4.38	$-3.91	$-4.01	$-4.12	$-4.97	$-4.70	$-3.74	$-1.90	$-4.23	$-4.12	$-4.78	$-4.85	$-4.80	$-3.86
Low Forecast	$0.99	$0.49	$0.36	$0.13	$-0.21	$-0.31	$-0.43	$-1.19	$-1.68	$-1.17	$-2.30	$-3.25	$-4.80	$-3.55	$-3.53	$-3.84	$-4.86	$-3.91	$-4.01	$-4.12	$-4.97	$-4.70	$-3.74	$-1.90	$-4.23	$-4.12	$-4.78	$-4.85	$-4.80	$-3.86
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.47%	1.08%	0.91%	0.93%	1.38%	1.39%	1.03%	1.24%	1.00%	1.39%	-0.41%	1.23%	1.17%	0.90%	0.97%	1.33%	1.31%

According to 6 Wall Street analysts, BeiGene's projected average Quarter EPS for Dec 23 is $-3.49, with a low estimate of $-4.80 and a high estimate of $-1.09. This represents a -320.81% decrease compared to BGNE previous annual EPS of $1.58 (Sep 23).

BeiGene Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IMAB	I-Mab	$0.95	$35.00	3584.21%	Buy
LEGN	Legend Biotech	$34.68	$89.60	158.36%	Buy
APLS	Apellis Pharmaceuticals	$34.53	$70.80	105.04%	Buy
IMVT	Immunovant	$27.91	$51.00	82.73%	Buy
PCVX	Vaxcyte	$89.86	$148.80	65.59%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
IONS	Ionis Pharmaceuticals	$37.68	$58.33	54.80%	Buy
ASND	Ascendis Pharma	$140.30	$211.14	50.49%	Buy
BGNE	BeiGene	$179.06	$267.33	49.30%	Buy
BMRN	BioMarin Pharmaceutical	$67.19	$94.43	40.54%	Buy
INCY	Incyte	$69.40	$90.11	29.84%	Buy
BPMC	Blueprint Medicines	$96.48	$122.60	27.07%	Buy
TVTX	Travere Therapeutics	$17.14	$21.75	26.90%	Buy
ARWR	Arrowhead Pharmaceuticals	$22.27	$27.74	24.56%	Buy
KRYS	Krystal Biotech	$169.04	$210.33	24.43%	Buy

BGNE Forecast FAQ

Is BeiGene a good buy?

Yes, according to 11 Wall Street analysts, BeiGene (BGNE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 72.73% of BGNE's total ratings.

What is BGNE's price target?

BeiGene (BGNE) average price target is $267.33 with a range of $207 to $307, implying a 51.50% from its last price of $176.45. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will BeiGene stock go up soon?

According to Wall Street analysts' prediction for BGNE stock, the company can go up by 51.50% (from the last price of $176.45 to the average price target of $267.33), up by 73.99% based on the highest stock price target, and up by 17.31% based on the lowest stock price target.

Can BeiGene stock reach $300?

BGNE's highest twelve months analyst stock price target of $307 supports the claim that BeiGene can reach $300 in the near future.

What is BeiGene's current price target trend?

1 Wall Street analyst forecast a $207 price target for BeiGene (BGNE) this month, up 17.31% from its last price of $176.45. Compared to the last 3 and 12 months, the average price target increased by 17.31% and increased by 53.73%, respectively.

What are BeiGene's analysts' financial forecasts?

BeiGene's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.56B (high $4.73B, low $4.36B), average EBITDA is $-4.064B (high $-3.887B, low $-4.218B), average net income is $-183M (high $-138M, low $-227M), average SG&A $4.75B (high $4.93B, low $4.54B), and average EPS is $-1.727 (high $-1.307, low $-2.142). BGNE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $5.17B (high $5.37B, low $4.95B), average EBITDA is $-4.61B (high $-4.413B, low $-4.785B), average net income is $221.14M (high $232.09M, low $208.86M), average SG&A $5.38B (high $5.59B, low $5.15B), and average EPS is $2.09 (high $2.19, low $1.97).

Did the BGNE's actual financial results beat the analysts' financial forecasts?

Based on BeiGene's last annual report (Dec 2023), the company's revenue was $2.46B, beating the average analysts forecast of $2.18B by 12.84%. Apple's EBITDA was $-1.208B, missing the average prediction of $-2.042B by -40.86%. The company's net income was $-882M, missing the average estimation of $-1.629B by -45.88%. Apple's SG&A was $1.5B, missing the average forecast of $2.18B by -30.87%. Lastly, the company's EPS was $-0.0006, missing the average prediction of $-13.898 by -100.00%. In terms of the last quarterly report (Sep 2023), BeiGene's revenue was $781.31M, beating the average analysts' forecast of $596.75M by 30.93%. The company's EBITDA was $-134M, missing the average prediction of $-532M by -74.82%. BeiGene's net income was $215.41M, missing the average estimation of $-358M by -160.09%. The company's SG&A was $364.42M, missing the average forecast of $621.33M by -41.35%. Lastly, the company's EPS was $1.58, missing the average prediction of $-3.385 by -146.68%